Guo Yingjia, Feng Li, Zhou Yanni, Sheng Jiantong, Long Dan, Li Shengfu, Li Youping
Key Laboratory of Transplant Engineering and Immunology of National Health and Family Planning Commission of the People's Republic of China, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
Key Laboratory of Transplant Engineering and Immunology of National Health and Family Planning Commission of the People's Republic of China, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China; Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
Transplant Rev (Orlando). 2015 Jul;29(3):127-34. doi: 10.1016/j.trre.2015.05.001. Epub 2015 May 7.
Ischemia-reperfusion injury (IRI) induces inevitable complications in liver transplantation. Many studies have demonstrated that hypoxia-inducible factor 1α (HIF-1α) plays an important role in IRI. However, the mechanism of its pleiotropic effect remains unclear. This systematic review provides a comprehensive evaluation of all available evidence concerning the function of HIF-1α in transplant-induced hepatic IRI. Data were obtained through a search of Medline (PubMed), Embase, and the Cochrane Library literature review on the effect of HIF-1α in IRI (from inception to 12/2014). RevMan was used to calculate standardized mean difference (SMD) and 95% confidence intervals (CIs). Forty articles met inclusion criteria with 2 clinical and 38 basic studies. Two clinical trials (n = 68) revealed ischemic preconditioning (IPC) aroused protection after hepatic IRI based on the higher level of HIF-1α in IPC group compared with control group. In vitro studies confirmed the salutary effect of IPC disappearance in the inhabitation of stabilized HIF-1α. In vivo animal studies showed different HIF-1α expression and distribution patterns in the ischemia and reperfusion stage due to distinctive partial oxygen pressure gradient intra-liver, and 5 animal studies (n=66) showed that stabilized HIF-1α treatment was associated with lower alanine aminotransferase (ALT) (SMD = -1.58; 95% CI =- 2.65, -0.52) when compared with unstabilized HIF-1α group. Not only decreased liver IR injury, stabilized HIF-1α during the acute phase of IR could also promote graft regeneration capacity leading to better initial function and survival rate. More rigorous studies are needed to gauge the effectiveness due to insufficient sample size and possible publication bias.
缺血再灌注损伤(IRI)在肝移植中会引发不可避免的并发症。许多研究表明,缺氧诱导因子1α(HIF-1α)在IRI中起重要作用。然而,其多效性作用的机制仍不清楚。本系统评价对所有关于HIF-1α在移植诱导的肝IRI中功能的现有证据进行了全面评估。通过检索Medline(PubMed)、Embase和Cochrane图书馆关于HIF-1α在IRI中作用的文献综述(从创刊到2014年12月)获取数据。使用RevMan计算标准化均数差(SMD)和95%置信区间(CI)。40篇文章符合纳入标准,其中2篇为临床研究,38篇为基础研究。两项临床试验(n = 68)显示,基于缺血预处理(IPC)组中HIF-1α水平高于对照组,缺血预处理在肝IRI后引起保护作用。体外研究证实了IPC消失在稳定HIF-1α抑制中的有益作用。体内动物研究表明,由于肝内独特的局部氧分压梯度,在缺血和再灌注阶段HIF-1α的表达和分布模式不同,5项动物研究(n = 66)表明,与未稳定化HIF-1α组相比,稳定化HIF-1α治疗与较低的丙氨酸转氨酶(ALT)相关(SMD = -1.58;95% CI = -2.65,-0.52)。稳定化HIF-1α不仅可减轻肝脏IR损伤,在IR急性期还可促进移植物再生能力,从而带来更好的初始功能和生存率。由于样本量不足和可能的发表偏倚,需要更严格的研究来评估其有效性。